American Journal of Clinical and Experimental Medicine

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Research Article |

Retrospective Analysis of Three Different Methods for the Treatment of Macrolide-Unresponsive Mycoplasma Pneumoniae Pneumonia in Children

Mycoplasma pneumoniae (MP) is an important cause of community-acquired pneumonia in children and adolescents. We screened 52 children with macrolide-unresponsive Mycoplasma pneumoniae pneumonia hospitalized at our institution from April 2023 to August 2023, and counted and evaluated their treatment modalities and efficacy. Based on the three different drug treatments, we divided all the children into four groups: Group A was the azithromycin oral sequential + glucocorticoid treatment effective group; Group B was the doxycycline oral treatment effective group; Group C was the doxycycline oral + glucocorticoid effective group. By χ2 test, Kruskal-Wallis test, and ann-WhitneyU rank-sum test, we compared the effective cure rate, adjusted hospitalization days, effective fever recovery time, and pulmonary imaging regression under different treatment modalities. We chose three groups of treatment effective cases, A, B and C to analyze. There was no statistically significant difference in the effective cure rate among the three effective groups, P > 0.05; There was a statistically significant difference in the number of adjusted hospitalization days, p < 0.05; There was a statistical difference in the number of adjusted hospitalization days between groups A and B, P < 0.05; There was a statistical difference in the number of adjusted hospitalization days between groups A and C, P < 0.05; There was no statistically significant difference in the number of adjusted hospitalization days between groups B and C, P > 0.05; There was no statistical difference in effective temperature recovery time or lung imaging outcomes among the three groups. From the study, we conclude that the choice of doxycycline or doxycycline and hormone therapy can shorten the number of days of hospitalization and achieve clinical cure more quickly.

Macrolide-Unresponsive Mycoplasma Pneumoniae Pneumonia, Doxycycline, Azithromycin, Glucocorticoid

APA Style

Linfang, W. (2023). Retrospective Analysis of Three Different Methods for the Treatment of Macrolide-Unresponsive Mycoplasma Pneumoniae Pneumonia in Children. American Journal of Clinical and Experimental Medicine, 11(5), 92-96. https://doi.org/10.11648/j.ajcem.20231105.12

ACS Style

Linfang, W. Retrospective Analysis of Three Different Methods for the Treatment of Macrolide-Unresponsive Mycoplasma Pneumoniae Pneumonia in Children. Am. J. Clin. Exp. Med. 2023, 11(5), 92-96. doi: 10.11648/j.ajcem.20231105.12

AMA Style

Linfang W. Retrospective Analysis of Three Different Methods for the Treatment of Macrolide-Unresponsive Mycoplasma Pneumoniae Pneumonia in Children. Am J Clin Exp Med. 2023;11(5):92-96. doi: 10.11648/j.ajcem.20231105.12

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Wang X, Li M, Luo M, et al. Mycoplasma pneumoniae triggers pneumonia epidemic in autumn and winter in Beijing: a multicentre, population-based epidemiological study between 2015 and 2020. Emerg Microbes Infect. 2022. 11 (1): 1508-1517.
2. Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev. 2017. 30 (3): 747-809.
3. Li ZJ, Zhang HY, Ren LL, et al. Etiological and epidemiological features of acute respiratory infections in China. Nat Commun. 2021, 12 (1): 5026.
4. Kevat PM, Morpeth M, Graham H, Gray AZ. A systematic review of the clinical features of pneumonia in children aged 5-9 years: Implications for guidelines and research. J Glob Health. 2022; 12: 10002.
5. Zhou Y, Shan Y, Cui Y, et al. Characteristics and Outcome of Severe Mycoplasma pneumoniae Pneumonia Admitted to PICU in Shanghai: A Retrospective Cohort Study. Crit Care Explor. 2021. 3 (3): e366.
6. Yan C, Xue G, Zhao H, Feng Y, Li S, Cui J, Ni S, Sun H. Molecular and clinical characteristics of severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2019; 54 (7): 1012-1021.
7. Liu X, Jiang Y, Chen X, Li J, Shi D, Xin D. Drug resistance mechanisms of Mycoplasma pneumoniae to macrolide antibiotics. Biomed Res Int. (2014) 2014: 320801. 10.1155/2014/320801.
8. Yang HJ, Song DJ, Shim JY. Mechanism of resistance acquisition and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. (2017) 60 (6): 167–74. 10.3345/kjp.2017.60.6.167.
9. Lucier TS, Heitzman K, Liu SK, Hu PC. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob Agents Chemother. 1995 Dec; 39 (12): 2770-3. doi: 10.1128/AAC.39.12.2770.
10. Suzuki Y, Shimotai Y, Itagaki T, Seto J, Ikeda T, Yahagi K, Mizuta K, Hongo S, Matsuzaki Y. Development of macrolide resistance-associated mutations after macrolide treatment in children infected with Mycoplasma pneumoniae. J Med Microbiol. 2017 Nov; 66 (11): 1531-1538. doi: 10.1099/jmm.0.000582. Epub 2017 Oct 6.
11. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, Sasaki Y, Arakawa Y, Sasaki T. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol. 2001; 45 (8): 617-20. doi: 10.1111/j.1348-0421.2001.tb01293.x.
12. Kumar S, Roy RD, Sethi GR, Saigal SR. Mycoplasma pneumoniae infection and asthma in children. Trop Doct. 2019; 49 (2): 117-119.
13. Lee H, Yun KW, Lee HJ, Choi EH. Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Expert Rev Anti Infect Ther. 2018 Jan; 16 (1): 23-34. doi: 10.1080/14787210.2018.1414599. Epub 2017 Dec 11.
14. Wang N, Zhang H, Yin Y, Xu X, Xiao L, Liu Y. Antimicrobial Susceptibility Profiles and Genetic Characteristics of Mycoplasma pneumoniae in Shanghai, China, from 2017 to 2019. Infect Drug Resist. 2022 Aug 11; 15: 4443-4452. doi: 10.2147/IDR.S370126.
15. Volovitz B, Shkap R, Amir J, Calderon S, Varsano I, Nussinovitch M. Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr. (2007) 46 (2): 121–6. 10.1177/0009922806290026.
16. Yang J, Wen S, Kong J, Yue P, Cao W, Xu X, Zhang Y, Chen J, Liu M, Fan Y, Luo L, Chen T, Li L, Li B, Dong Y, Luo S, Zhou G, Liu A, Bao F. Forty Years of Evidence on the Efficacy and Safety of Oral and Injectable Antibiotics for Treating Lyme Disease of Adults and Children: A Network Meta-Analysis. Microbiol Spectr. 2021; 9 (3): e0076121.
17. Rhim JW, Kang JH, Lee KY. Etiological and pathophysiological enigmas of severe coronavirus disease 2019, multisystem inflammatory syndrome in children, and Kawasaki disease. Clin Exp Pediatr. (2022) 65 (4): 153–66. 10.3345/cep.2021.01270.
18. Zhang H, Sun C, Yu Z. Effect of azithromycin sequential therapy combined with budesonide nebulization on chest CT changes in children with mycoplasma pneumonia. Minerva Gastroenterol (Torino). 2023 Sep; 69 (3): 447-449. doi: 10.23736/S2724-5985.23.03373-9. Epub 2023 Apr 3.
19. Yang EA, Kang HM, Rhim JW, Kang JH, Lee KY. Early corticosteroid therapy for Mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children. J Clin Med. (2019) 8 (5): 726. 10.3390/jcm8050726.